Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

NCT03299049 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1049

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Cabotegravir Tablets
DRUG: Rilpivirine Tablets
DRUG: Cabotegravir Injectable Suspension
DRUG: Rilpivirine Injectable Suspension

Sponsor

ViiV Healthcare

Collaborators

[object Object]